PURE Bioscience (OTCMKTS:PURE) CEO Henry R. Lambert sold 41,500 shares of PURE Bioscience stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $0.93, for a total transaction of $38,595.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
PURE Bioscience (OTCMKTS PURE) opened at $0.94 on Friday. PURE Bioscience has a 12 month low of $0.83 and a 12 month high of $1.36.
PURE Bioscience (OTCMKTS:PURE) last issued its earnings results on Thursday, October 26th. The company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). PURE Bioscience had a negative net margin of 388.83% and a negative return on equity of 210.88%. analysts predict that PURE Bioscience will post -0.08 earnings per share for the current year.
Separately, ValuEngine downgraded shares of PURE Bioscience from a “hold” rating to a “sell” rating in a research note on Friday, November 10th.
PURE Bioscience Company Profile
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.